Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions

Journal of Neurochemistry

Volumn 66, Issue 1, 1996, Pages 243-249

  Gudelsky, Gary A ^a,c   Nash, J Frank ^b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

3,4 methylenedioxymethamphetamine; Dopamine; Serotonin

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; BRAIN SLICE; COMPETITIVE INHIBITION; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; MEMBRANE VESICLE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SYNAPTOSOME;

5-HYDROXYTRYPTOPHAN; ANIMALS; CARBIDOPA; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DRUG SYNERGISM; FLUOXETINE; FRONTAL LOBE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN AGENTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TETRODOTOXIN;

ANIMALIA;

EID: 0030070015     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1996.66010243.x     Document Type: Article

References (44)

1. 2+-dependent toxicity linked to release. Brain Res. 510, 97-103.
2. Battaglia G., Yeh S. Y., and De Souza E. B. (1988) MDMA-induced neurotoxicity: parameters of degeneration and recovery of brain serotonin neurons. Pharmacol. Biochem. Behav. 29, 269-274.
3. Battaglia G., Sharkey J., Kuhar M. J., and De Souza E B. (1991) Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography. Synapse 8, 249-260.
4. Berger U. V., Gu X. F., and Azmitia E. C. (1992) The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 215, 153-160.
5. Brodkin J., Malyala A., and Nash J. F. (1993) Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity Pharmacol. Biochem. Behav. 45, 647-653.
6. Carboni E. and Di Chiara G. (1989) Serotonin release estimated by transcortical dialysis in freely moving rats. Neuroscience 32, 637-645.
7. Commins D. L., Vosmer G., Virus R. M., Woolverton W. L., Schuster C. R., and Seiden L S. (1987) Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241, 338-345.
8. Fitzgerald J. L. and Reid J. J. (1993) Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn Schmiedebergs Arch. Pharmacol. 347, 313-323.
9. Gartside S. E., Cowen P. J., and Sharp T. (1992) Effect of 5-hydroxy-L-tryptophan on the release of 5-HT in rat hypothalamus in vivo as measured by microdialysis. Neuropharmacology 31, 9-14.
10. Gough B., Ali S. F., Slikker W. Jr., and Holson R. (1991) Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate. Pharmacol. Biochem. Behav. 39, 619-623.
11. Gu X. F. and Azmitia E. C. (1993) Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur. J. Pharmacol. 235, 51-57.
12. 2 agonists. Eur. J. Pharmacol. 264, 325-330.
13. Hekmatpanah C. R. and Peroutka S. J. (1990) 5-Hydroxytryptamine uptake blockers attenuate the 5-hydroxytryptamine-releasing effect of 3,4-methylenedioxymethamphetamine and related agents. Eur. J. Pharmacol. 177, 95-98.
14. Hiramatsu M. and Cho A. K. (1990) Enantiomeric differences in the effects of 3,4-methylenedioxymethamphetamine on extracellular monoamines and metabolites in the striatum of freely-moving rats: an in vivo microdialysis study. Neuropharmacology 29, 269-275.
15. Iyer R. N., Sprouse J. S., Aghajanian G. K., Roth R. H., and Bradberry C. W. (1994) Tryptophan pretreatment augmentation of p-chloroamphetamine-induced serotonin and dopamme release and reduction of long-term neurotoxicity. Biochem. Pharmacol. 48, 1501-1508.
16. 3H]dopamine release from superfused rat brain slices. Eur. J. Pharmacol. 132, 269-276.
17. 3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur. J. Pharmacol. 200, 9-16.
18. 3H-5-hydroxytryptamine. Pharmacol. Biochem. Behav. 38, 505-512.
19. Meltzer H. Y. and Nash J. F. (1991) The effects of antipsychotic drugs on serotonergic receptors. Pharmacol. Rev. 43, 587-604.
20. Nash J. F. (1990) Ketanserin pretreatment blocks MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sci. 47, 2401-2408.
21. Nash J. F. and Brodkin J. (1991) Microdialysis studies on 3,4-methylenedioxymethamphetamine induced dopamine release: effect of dopamine uptake inhibitors. J. Pharmacol. Exp. Ther. 259, 820-825.
22. Nash J. F., Meltzer H. Y., and Gudelsky G. A. (1990) Effect of 3,4-methylenedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. J. Neurochem. 54, 1062-1067.
23. 3H]serotonin from rat brain synaptosomes. J. Med. Chem. 25, 530-535.
24. Nomikos G. G., Damsma G., Wenkstern D., and Fibiger H. C. (1990) In vivo characterization of locally applied dopamine uptake inhibitors by striatal microdialysis. Synapse 6, 106-112.
25. O'Hearn E., Battaglia G., De Souza E. B., Kuhar M. J., and Molliver M. E. (1988) Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J. Neurosci. 8, 2788-2803.
26. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, New York.
27. Perry K. and Fuller R. W. (1993) Extracellular 5-hydroxytryptamine concentration in rat hypothalamus after administration of fluoxetine plus L-5-hydroxytryptophan. J. Pharm. Phamacol. 45, 759-761.
28. Ricaurte G. A., Forno L. S., Wilson M. A., DeLanney L. E., Irwin I., Molliver M. E., and Langston J. W. (1988) 3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. JAMA 260, 51-55.
29. Rudnick G. and Wall S. C. (1992) The molecular mechanism of Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. USA 89, 1817-1821.
30. Schmidt C. J. (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240, 1-7.
31. Schmidt C. J. and Lovenberg W. (1985) In vitro demonstration of dopamine uptake by neostriatal serotonergic neurons of the rat. Neurosci. Lett. 59, 9-14.
32. 2 receptors exert a state-dependent regulation of dopaminergic fucnction: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 223, 65-74.
33. 2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. J. Neurochem. 62, 1382-1389.
34. Seiden L. S., Sabol K. E., and Ricaurte G. (1993) Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. 32, 639-677.
35. Sprague J. E. and Nichols D. E. (1995) The monoamine oxidase inhibitor l-deprenyl protects against 3,4-methylenedioxymethamphetamine induced lipid peroxidation and long term serotonergic deficits. J. Pharmacol. Exp. Ther. 273, 667-673.
36. Sprague J. E., Huang X., Kanthasamy A., and Nichols D. E. (1995) Attenuation of 3,4-methylenedioxymethamphetamine (MDMA) induced neurotoxicity with the serotonin precursors tryptophan and 5-hydroxytryptophan. Life Sci. 55, 1193-1198.
37. Sprouse J. S., Bradberry C. W., Roth R. H., and Aghajanian G. K. (1989) MDMA (3,4-methylenedioxymethamphetamine) inhibits the firing of dorsal raphe neurons in brain slices via release of serotonin. Eur. J. Pharmacol. 167, 375-383.
38. 3H]monoamines into synaptosomes from different regions of rat brain. Biochem. Pharmacol. 36, 2297-2303.
39. Stone D. M., Merchant K. M., Hanson G. R., and Gibb J. W. (1987) Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26, 1677-1683.
40. Stone D. M., Hanson G. R., and Gibb J. W. (1989) In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine. J. Neurochem. 53, 572-581.
41. Westerink B. H. C., Tuntler J., Damsma G., Rollema H., and de Vries J. B. (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamrae release in conscious rats studied by brain dialysis. Arch. Pharmacol. 336, 502-507.
42. White S. R., Duffy P., and Kalivas P. W. (1994) Methylenedioxymethamphetamine depresses glutamate-evoked neuronal firing and increases extracellular levels of dopamine and serotonin in the nucleus accumbens. Neuroscience 62, 41-50.
43. Yamamoto B. K. and Spanos L. J. (1988) The acute effects of methylenedioxymethamphetamine on dopamine release in the awake-behaving rat. Eur. J. Pharmacol. 148, 195-203.
44. Yamamoto B. K., Nash J. F., and Gudelsky G. A. (1995) Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and GABA in the substantia nigra. J. Pharmacol. Exp. Ther. 273, 1063-1070.